炎症性肠病治疗中启动抗肿瘤坏死因子时停用硫嘌呤的影响:丹麦全国队列研究
该丹麦全国队列研究纳入2003至2018年启动抗肿瘤坏死因子(anti-TNF)前正在使用硫嘌呤的炎症性肠病(IBD)患者,比较启动anti-TNF后90天内停用与继续使用硫嘌呤者的复合不良结局。停用硫嘌呤与主要结局风险升高相关(aHR 1.22;95%CI 1.10-1.36),克罗恩病和溃疡性结肠炎中均可见此风险升高。
要点
- 启动anti-TNF后90天内停用硫嘌呤与主要复合结局风险升高相关(aHR 1.22;95%CI 1.10-1.36)。
- 该风险升高在克罗恩病(aHR 1.17;95%CI 1.02-1.34)和溃疡性结肠炎(aHR 1.32;95%CI 1.12-1.55)中均可见。
- 需要进一步开展干预性研究探索这一常见临床情景。
核心结论
- 在IBD全国队列中,启动anti-TNF后停用硫嘌呤与不良结局风险升高相关,尤其是住院增加。
- 需要进一步开展干预性研究探索这一常见临床情景。
研究设计与样本
- 使用丹麦登记数据建立2003至2018年启动anti-TNF前正在使用硫嘌呤的IBD患者全国队列。
- 比较启动anti-TNF后90天内停用硫嘌呤者与继续使用者。
- 主要结局为任何新口服糖皮质激素使用、IBD相关住院、手术或死亡的复合终点。
- 采用Cox回归模型计算校正风险比(aHR)和95%置信区间(CI)。
主要发现
- 10,352例anti-TNF暴露患者中,2,630例(克罗恩病1,590例,溃疡性结肠炎1,040例)在anti-TNF前接受硫嘌呤。
- 启动anti-TNF后,979例患者停用硫嘌呤。
- 启动anti-TNF后90天内停用硫嘌呤增加主要结局风险(aHR 1.22;95%CI 1.10-1.36)。
- IBD相关住院风险升高(aHR 1.14;95%CI 1.00-1.31),口服糖皮质激素使用风险升高(aHR 1.27;95%CI 1.13-1.44)。
- 主要结局风险升高见于克罗恩病(aHR 1.17;95%CI 1.02-1.34)和溃疡性结肠炎(aHR 1.32;95%CI 1.12-1.55)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步开展干预性研究探索这一常见临床情景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Escalation to anti-tumour necrosis factor (anti-TNF) in inflammatory bowel disease (IBD) patients on thiopurine is a common clinical scenario. However, the impact of discontinuing thiopurine at escalation is unclear. AIM: To assess the impact of discontinuing versus continuing thiopurine therapy at anti-TNF initiation. METHODS: We used the Danish registries to establish a national cohort of patients with IBD on thiopurine therapy prior to initiating anti-TNF from 2003 to 2018. We compared patients discontinuing thiopurine therapy within 90 days of anti-TNF initiation to those continuing. Our primary outcome was a composite of any new oral corticosteroid use, IBD-related hospitalization, surgery or death. We used Cox regression models to calculate adjusted hazard ratios (aHR) and 95% confidence intervals (CI). RESULTS: Of the 10,352 anti-TNF exposed patients, 2,630 (1590 Crohn's disease (CD) and 1040 ulcerative colitis (UC)) received thiopurines prior to anti-TNF. After anti-TNF initiation, 979 patients discontinued thiopurines. Discontinuing thiopurines within 90 days of anti-TNF initiation, increased the risk of the primary outcome (aHR: 1.22; 95% CI: 1.10-1.36), particularly for IBD-related hospitalization (aHR: 1.14; 95% CI: 1.00-1.31) and oral corticosteroid use (aHR: 1.27; 95% CI: 1.13-1.44). This increased risk of the primary outcome was seen in both CD (aHR: 1.17; 95% CI 1.02-1.34) and UC (aHR: 1.32; 95% CI: 1.12-1.55). CONCLUSIONS: In a nationwide cohort study of IBD patients, we observed that discontinuing thiopurines after anti-TNF initiation was associated with an increased risk of adverse outcomes, in particular an increase in hospitalizations. Further interventional studies exploring this common clinical scenario are required.
引用
- Thomsen SB, Ungaro RC, Allin KH, et al. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study. Aliment Pharmacol Ther. 2022. PMID: 35080036. doi:10.1111/apt.16777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。